2023
Optogenetic Control of Oncogenic Signaling in B-Cell Malignancies
Kume K, Lee J, Cheng Z, Robinson M, Leveille E, Cosgun K, Chan L, Feng Y, Arce D, Khanduja D, Toomre D, Müschen M. Optogenetic Control of Oncogenic Signaling in B-Cell Malignancies. Blood 2023, 142: 4138. DOI: 10.1182/blood-2023-190926.Peer-Reviewed Original ResearchB-cell malignanciesB-cell lymphomaMature B-cell lymphomasB cell deathB cellsB cell developmentGenetic deletionMantle cell lymphomaNF-kB signalingBCR signal inhibitorsB cell precursorsCell of originCell viabilityChronic active BCRB cell survivalB cell receptor signalsHodgkin's diseaseMultiple myelomaNormal B cell developmentPlasma cellsBtk tyrosine kinaseCell lymphomaBurkitt's lymphomaNF-kBSmall molecule inhibitors
2013
The Plasma Cell Transcription Factor XBP1 is Required To Mitigate The Unfolded Protein Response In Ph+ ALL
Masouleh B, Geng H, Hurtz C, Huang C, Chan L, Swaminathan S, Sun H, Koeffler H, Melnick A, Paietta E, Glimcher L, Muschen M. The Plasma Cell Transcription Factor XBP1 is Required To Mitigate The Unfolded Protein Response In Ph+ ALL. Blood 2013, 122: 836. DOI: 10.1182/blood.v122.21.836.836.Peer-Reviewed Original ResearchRelapse-free survivalX-box binding protein 1White blood cell countPR domain zinc finger protein 1Minimal residual diseaseLeukemia-initiating cellsOverall survivalMultiple myelomaPlasma cellsB cellsClinical relevanceWorse relapse-free survivalUnfolded protein responseXBP1 activationHigh expressionOnset of chemotherapyLeukemia cellsPoor overall survivalBlood cell countInducible CreProtein 1Improved treatment optionsBCR-ABL1 kinase activityTranscription factor X-box binding protein 1Bone marrow B cells
2012
Targeting the UPR-Transcription Factor XBP1 to Overcome Drug-Resistance in Ph+ ALL
Masouleh B, Hurtz C, Geng H, Ramezani-Rad P, Glimcher L, Muschen M. Targeting the UPR-Transcription Factor XBP1 to Overcome Drug-Resistance in Ph+ ALL. Blood 2012, 120: 872. DOI: 10.1182/blood.v120.21.872.872.Peer-Reviewed Original ResearchX-box binding protein 1Relapse-free survivalMultiple myelomaSTF-083010Overall survivalPlasma cellsMinimal residual disease statusPKR-like ER kinaseOnset of chemotherapyLeukemia cellsResidual disease statusPoor overall survivalInducible CreImproved treatment optionsPlasma cell malignancyBone marrow B cell precursorsBone marrow progenitor cellsPresence of IL7ER stressTransplant recipient micePotential clinical relevanceUnfolded protein responseNormal bone marrowB cell precursorsMarrow progenitor cells